AMG 900, pan-Aurora kinase inhibitor, preferentially inhibits the proliferation of breast cancer cell lines with dysfunctional p53

p53-Mediated Senescence Impairs the Apoptotic Response to Chemotherapy and Clinical Outcome in Breast Cancer

(2012) James G. Jackson et al.   CANCER CELL

Predictive Biomarkers of Sensitivity to the Aurora and Angiogenic Kinase Inhibitor ENMD-2076 in Preclinical Breast Cancer Models

(2012) J. R. Diamond et al.   CLINICAL CANCER RESEARCH

Treatment of human pre-B acute lymphoblastic leukemia with the Aurora kinase inhibitor PHA-739358 (Danusertib)

(2012) Fei Fei et al.   Molecular Cancer

Inhibiting Aurora Kinases Reduces Tumor Growth and Suppresses Tumor Recurrence after Chemotherapy in Patient-Derived Triple-Negative Breast Cancer Xenografts

(2012) A. Romanelli et al.   MOLECULAR CANCER THERAPEUTICS

Dacomitinib (PF-00299804), an Irreversible Pan-HER Inhibitor, Inhibits Proliferation of HER2-Amplified Breast Cancer Cell Lines Resistant to Trastuzumab and Lapatinib

(2012) O. Kalous et al.   MOLECULAR CANCER THERAPEUTICS

Transcriptional analysis of the Aurora inhibitor Danusertib leading to biomarker identification in TP53 wild type cells

(2011) Roberta Bosotti et al.   GENE

p53: Guardian of ploidy

(2011) Yael Aylon et al.   Molecular Oncology

BPR1K653, a Novel Aurora Kinase Inhibitor, Exhibits Potent Anti-Proliferative Activity in MDR1 (P-gp170)-Mediated Multidrug-Resistant Cancer Cells

(2011) Chun Hei Antonio Cheung et al.   PLoS One

Subtype and pathway specific responses to anticancer compounds in breast cancer

(2011) L. M. Heiser et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Aurora kinases A and B are up-regulated by Myc and are essential for maintenance of the malignant state

(2010) J. den Hollander et al.   BLOOD

A novel Aurora-A kinase inhibitor MLN8237 induces cytotoxicity and cell-cycle arrest in multiple myeloma

(2010) G. Gorgun et al.   BLOOD

Preclinical Evaluation of AMG 900, a Novel Potent and Highly Selective Pan-Aurora Kinase Inhibitor with Activity in Taxane-Resistant Tumor Cell Lines

(2010) M. Payton et al.   CANCER RESEARCH

Combination of nutlin-3 and VX-680 selectively targets p53 mutant cells with reversible effects on cells expressing wild-type p53

(2010) C F Cheok et al.   CELL DEATH AND DIFFERENTIATION

Sensitivity of BRCA2 mutated human cell lines to Aurora kinase inhibition

(2010) Linda Vidarsdottir et al.   INVESTIGATIONAL NEW DRUGS

The FLT3 Internal Tandem Duplication Mutation Is a Secondary Target of the Aurora B Kinase Inhibitor AZD1152-HQPA in Acute Myelogenous Leukemia Cells

(2010) M. Grundy et al.   MOLECULAR CANCER THERAPEUTICS

Targets and effectors of the cellular response to aurora kinase inhibitor MK-0457 (VX-680) in imatinib sensitive and resistant chronic myelogenous leukemia

(2009) Nicholas J. Donato et al.   BIOCHEMICAL PHARMACOLOGY

Aurora kinase inhibitor ZM447439 induces apoptosis via mitochondrial pathways

(2009) Minglun Li et al.   BIOCHEMICAL PHARMACOLOGY

Aurora kinase inhibitors in preclinical and clinical testing

(2009) Chun Hei Antonio Cheung et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Aurora B Kinase Regulates the Postmitotic Endoreduplication Checkpoint via Phosphorylation of the Retinoblastoma Protein at Serine 780

(2009) Jayasree S. Nair et al.   MOLECULAR BIOLOGY OF THE CELL

Determinants for the efficiency of anticancer drugs targeting either Aurora-A or Aurora-B kinases in human colon carcinoma cells

(2009) P. Kaestner et al.   MOLECULAR CANCER THERAPEUTICS

Aurora Kinase A Inhibition Leads to p73-Dependent Apoptosis in p53-Deficient Cancer Cells

(2008) Altaf A. Dar et al.   CANCER RESEARCH

TP53 Status and Response to Chemotherapy in Breast Cancer

(2008) Philippe Bertheau et al.   PATHOBIOLOGY